



SolAeroMed Inc  
Research Transition Facility  
3535 Research Rd NW  
Calgary T2L 2K8

email: [info@solaeromed.com](mailto:info@solaeromed.com)  
[www.solaeromed.com](http://www.solaeromed.com)

Newsletter #7 August 2, 2013

Dear SolAeroMed shareholders,

I write to update you on SolAeroMed progress, and plans for the near and medium term. Firstly, we invite you to attend our AGM 4pm Sept 5 2013 at our Calgary offices. We will arrange a dial in option for those who can't attend in person. We will make short presentations and invite shareholder approval of our Board, 2012 financials and will provide opportunity for discussion.

We are pleased to share news that we have raised sufficient funds to allow us to progress a first-in-man Phase I S-1226 Clinical trial, our lead asthma drug. We will partner with Toronto based PharmaMedica who specialize in conducting Phase I clinical studies. This will be SolAeroMed's first S-1226 clinical study and we will be dosing healthy human volunteers under strict medical supervision. We anticipate subjects will be dosed this fall. Our dosing protocol will initially deliver nebulized S-1226 with 4% CO<sub>2</sub>. Assuming no adverse events are observed, the protocol then progresses to higher 8%, and finally our highest dose of 12%. The entire Phase I trial should be completed and reported to Health Canada regulators early 2014. We anticipate no significant adverse events observed at these dose levels.

Assuming a successful Phase I, we plan to progress to a Phase IIa 'efficacy' trial in asthmatic patients later in 2014 for which we are working to secure additional finance. The S-1226 Phase IIa will explore dose-ranging, efficacy and safety in asthmatic patients.

We will inform SolAeroMed shareholders of further developments through [www.solaeromed.com](http://www.solaeromed.com) and these periodic newsletters.

Sincerely

Dr John H Dennis  
CEO